Varex Imaging (Nasdaq: VREX) grows Q1 2026 revenue 5% to $210M
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Varex Imaging Corporation reported a solid first quarter of fiscal 2026 with year-over-year growth and improved profitability. Revenue reached $209.6 million, up 5% from $199.8 million a year earlier, driven by a 17% year-over-year increase in Industrial segment revenue to $64.8 million, while Medical revenue was stable at $144.8 million.
GAAP net income attributable to Varex improved to $2.3 million, or $0.05 per diluted share, from a loss of $0.3 million, or $(0.01) per diluted share, in the prior-year quarter. Non-GAAP diluted net income per share increased to $0.19 from $0.10, and non-GAAP operating margin rose to 9.0%. Adjusted EBITDA grew to $28.5 million from $25.5 million.
Operating cash flow was a $16 million outflow, and cash, cash equivalents, and marketable securities declined to $125.6 million at quarter-end from $155.1 million at the end of fiscal 2025, primarily due to higher inventories. For the second quarter of fiscal 2026, the company expects revenue between $210 million and $225 million and non-GAAP net earnings per diluted share between $0.15 and $0.25.
Positive
- Profitability inflection and strong non-GAAP growth: GAAP results swung from a prior-year loss of $0.3 million to net income of $2.3 million, while non-GAAP net income rose to $8.0 million and non-GAAP diluted EPS increased from $0.10 to $0.19, indicating materially improved earnings performance.
Negative
- None.
Insights
Varex delivered profitable growth in Q1 2026 with stronger non-GAAP earnings and firm guidance.
Varex Imaging generated Q1 fiscal 2026 revenue of
Profitability improved meaningfully. GAAP net income attributable to Varex moved to
Cash flow was softer, with a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 10, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | |||||||||
(Address of principal executive offices) | (Zip Code) | ||||||||||
Registrant’s telephone number, including area code: (801 ) 972-5000
Not Applicable
(Former name or former address, if changed since last report)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b - 2 of the Securities Exchange Act of 1934. Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition | ||||
On February 10, 2026 , Varex Imaging Corporation (the “Company”) issued a press release announcing its preliminary results of operations for the three months ended January 2, 2026 entitled: “Varex Announces Financial Results for First Quarter Fiscal Year 2026.” A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference into this item.
This information shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits | ||||
(d) Exhibits
| Exhibit No. | Description | ||||
| 99.1 | Press Release dated February 10, 2026, entitled "Varex Announces Financial Results for First Quarter Fiscal Year 2026" | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VAREX IMAGING CORPORATION | ||||||||
Dated: | By: | /s/ Matthew A. Martinez | ||||||
| Matthew A. Martinez | ||||||||
| Chief Legal Officer and Corporate Secretary | ||||||||
Exhibit 99.1
 | ||
VAREX ANNOUNCES FINANCIAL RESULTS FOR
FIRST QUARTER FISCAL YEAR 2026
SALT LAKE CITY, February 10, 2026 – Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the first quarter fiscal year 2026.
Q1FY26 Summary
•Revenues $210 million
•GAAP gross margin 33% | Non-GAAP gross margin* 34%
•GAAP operating margin 7% | Non-GAAP operating margin* 9%
•GAAP net income $0.05 per diluted share | Non-GAAP net income* $0.19 per diluted share
•Cash outflow from operations of $16 million
"We are pleased to report a solid start to fiscal 2026, with results toward the high-end of guidance. First quarter revenue of $210 million, increased 5% year-over-year. Growth in the quarter was driven by strength in our cargo systems business, which contributed to a 17% year-over-year increase in Industrial segment revenue" said Sunny Sanyal, Chief Executive Officer. Sanyal added, "Looking ahead, we expect demand for CT products to remain strong and we are encouraged by the sustained momentum in our cargo security systems business."
Varex’s first quarter revenue of $210 million was up 5% year-over-year. Medical segment revenue was $145 million, while Industrial segment revenue was $65 million. Non-GAAP gross margin was 34% in the quarter compared to 35% in the first quarter of fiscal year 2025, and non-GAAP EPS increased to $0.19 in the quarter from $0.10 in the first quarter of fiscal year 2025.
Balance Sheet & Cash Flow
Cash outflow from operations was $16 million in the first quarter of fiscal year 2026. Cash, cash equivalents, and marketable securities was $126 million as of the end of the first quarter of 2026 compared to $155 million at the end of fiscal year 2025. The primary driver of the lower cash was an increase in working capital, primarily driven by inventory.
Outlook
Guidance for the second quarter of fiscal year 2026 is as follows:
•Revenues are expected to be between $210 million and $225 million
•Non-GAAP net earnings per diluted share is expected to be between $0.15 and $0.25
Guidance for the company's net earnings per diluted share is provided on a non-GAAP basis only. This non-GAAP financial measure is forward-looking, and the company is unable to provide a meaningful or accurate reconciliation to a GAAP forecast of net earnings per diluted share without unreasonable effort due to certain of these reconciling items being uncertain, out of its control, and the amount and timing of these items being unable to be reasonably predicted. The actual amounts of such reconciling items could have a significant impact on the company's GAAP net income (loss) per diluted share.
Non-GAAP Financial Measures
The company updated its non-GAAP policy related to equity-method investments beginning with the first quarter of fiscal year 2026. Please refer to "Reconciliation of 2025 Non-GAAP Financial Information As Previously Reported to 2025 Non-GAAP Financial Results as per Updated Policy - Excluding gains and losses from equity-method investments (Unaudited)" below.
Conference Call Information
Varex will conduct its earnings conference call for the first quarter of fiscal year 2026 today at 3:00 p.m. Mountain Time. The conference call, including a supplemental slide presentation, will be webcast live and can be accessed at Varex’s website at www.vareximaging.com/investor-relations. Access will also be available by dialing 877-524-8416 from anywhere in the U.S. or by dialing 412-902-1028 from non-U.S. locations. The webcast and supplemental slide presentation will be archived on Varex’s website at www.vareximaging.com/financial-reports. A replay of the call will be available from today through February 24th at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay access code is 13758188. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=seewOOWX
About Varex
Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit www.vareximaging.com.
Forward Looking Statements
This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning unaudited financial results; revenue and earnings guidance; industry or business outlook; product demand environment; expected future financial results or performance; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intend,” and “potential,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations. While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, actual results and developments will depend on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations. Such risks and uncertainties include: changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto; reduction in or loss of business of one or more of the company's limited original equipment manufacturing customers; global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars, and other risks associated with international manufacturing, operations and sales; loss of business to, and an inability to effectively compete with, competitors; pricing pressures and other factors that could result in market erosion or loss of customers; failure to meet customers’ needs and demands; supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components; disruption of critical information systems or material breaches in the security of such systems; inability to maintain or defend intellectual property rights, and cost associated with protecting the company's intellectual property and defending such rights and defending against infringement claims; non-compliance with regulations applicable to marketing, manufacturing, labeling, and distributing the company's products and delays in obtaining regulatory clearances or approvals; limitations imposed by operating and financial restrictions of the company's debt financing agreements; the financial results of the company's equity method investments and joint ventures, and the other risks listed from time to time in the company's filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause the company's actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
Varex has not filed its Form 10-Q for the first quarter of fiscal year 2026. All financial results described here should be considered preliminary and are subject to change to reflect any necessary adjustments or changes in accounting estimates that are identified prior to the time Varex files its Form 10-Q.
# # #
For Information Contact:
Christopher Belfiore
Director of Investor Relations
Varex Imaging Corporation
801.973.1566 | christopher.belfiore@vareximaging.com
VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended | |||||||||||
| (In millions, except for per share amounts) | January 2, 2026 | January 3, 2025 | |||||||||
| Revenues, net | |||||||||||
| Medical | $ | 144.8 | $ | 144.6 | |||||||
| Industrial | 64.8 | 55.2 | |||||||||
| Total revenues | 209.6 | 199.8 | |||||||||
| Cost of revenues | |||||||||||
| Medical | 98.8 | 95.1 | |||||||||
| Industrial | 41.0 | 36.2 | |||||||||
| Total cost of revenues | 139.8 | 131.3 | |||||||||
| Gross profit | |||||||||||
| Medical | 46.0 | 49.5 | |||||||||
| Industrial | 23.8 | 19.0 | |||||||||
| Total gross profit | 69.8 | 68.5 | |||||||||
| Operating expenses: | |||||||||||
| Research and development | 21.7 | 23.5 | |||||||||
| Selling, general, and administrative | 32.7 | 33.8 | |||||||||
| Total operating expenses | 54.4 | 57.3 | |||||||||
| Operating income | 15.4 | 11.2 | |||||||||
| Interest income | 0.6 | 2.1 | |||||||||
| Interest expense | (7.9) | (8.0) | |||||||||
| Other expense, net | (4.3) | (2.8) | |||||||||
| Interest and other expense, net | (11.6) | (8.7) | |||||||||
| Income before taxes | 3.8 | 2.5 | |||||||||
| Income tax expense | 1.4 | 2.6 | |||||||||
| Net income (loss) | 2.4 | (0.1) | |||||||||
| Less: Net income attributable to noncontrolling interests | 0.1 | 0.2 | |||||||||
| Net income (loss) attributable to Varex | $ | 2.3 | $ | (0.3) | |||||||
| Net income (loss) per common share attributable to Varex | |||||||||||
| Basic | $ | 0.06 | $ | (0.01) | |||||||
| Diluted | $ | 0.05 | $ | (0.01) | |||||||
| Weighted average common shares outstanding | |||||||||||
| Basic | 41.8 | 41.1 | |||||||||
| Diluted | 42.3 | 41.1 | |||||||||
VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except share and per share amounts) | January 2, 2026 | October 3, 2025 | |||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 119.5 | $ | 145.0 | |||||||
| Marketable securities | 6.1 | 10.1 | |||||||||
Accounts receivable, net of allowance for credit losses of $2.6 million and $2.1 million at January 2, 2026 and October 3, 2025, respectively | 146.5 | 156.6 | |||||||||
| Inventories, net | 328.0 | 299.4 | |||||||||
Prepaid expenses and other current assets | 33.5 | 30.7 | |||||||||
| Total current assets | 633.6 | 641.8 | |||||||||
| Property, plant, and equipment, net | 160.2 | 157.8 | |||||||||
| Goodwill | 198.4 | 198.4 | |||||||||
| Intangible assets, net | 14.7 | 14.0 | |||||||||
| Investments in privately-held companies | 21.3 | 24.5 | |||||||||
| Deferred tax assets | 2.9 | 2.9 | |||||||||
| Operating lease assets | 29.1 | 29.4 | |||||||||
| Other assets | 37.8 | 38.6 | |||||||||
| Total assets | $ | 1,098.0 | $ | 1,107.4 | |||||||
| Liabilities and stockholders' equity | |||||||||||
| Current liabilities: | |||||||||||
Accounts payable | $ | 78.9 | $ | 69.9 | |||||||
Accrued liabilities and other current liabilities | 65.7 | 98.4 | |||||||||
Current operating lease liabilities | 4.6 | 4.4 | |||||||||
| Current maturities of long-term debt, net | 1.4 | 1.5 | |||||||||
Deferred revenues | 12.4 | 13.0 | |||||||||
| Total current liabilities | 163.0 | 187.2 | |||||||||
| Long-term debt, net | 366.2 | 366.0 | |||||||||
| Deferred tax liabilities | 5.5 | 5.5 | |||||||||
| Operating lease liabilities | 23.3 | 24.0 | |||||||||
| Other long-term liabilities | 49.2 | 38.1 | |||||||||
| Total liabilities | 607.2 | 620.8 | |||||||||
| Stockholders' equity: | |||||||||||
| Preferred stock, $0.01 par value: 20,000,000 shares authorized, none issued | — | — | |||||||||
| Common stock, $0.01 par value: 150,000,000 shares authorized | |||||||||||
| Shares issued and outstanding: 41,919,432 and 41,689,672 at January 2, 2026 and October 3, 2025, respectively. | 0.4 | 0.4 | |||||||||
| Additional paid-in capital | 485.6 | 483.3 | |||||||||
| Accumulated other comprehensive loss | (5.5) | (5.2) | |||||||||
| Accumulated deficit | (3.6) | (5.9) | |||||||||
| Total Varex stockholders' equity | 476.9 | 472.6 | |||||||||
| Noncontrolling interests | 13.9 | 14.0 | |||||||||
| Total stockholders' equity | 490.8 | 486.6 | |||||||||
| Total liabilities and stockholders' equity | $ | 1,098.0 | $ | 1,107.4 | |||||||
VAREX IMAGING CORPORATION
RECONCILIATION BETWEEN GAAP AND NON-GAAP FINANCIAL MEASURES
(Unaudited)
| Three Months Ended | |||||||||||
| (In millions, except per share amounts) | January 2, 2026 | January 3, 2025 | |||||||||
| GROSS PROFIT RECONCILIATION | |||||||||||
| Revenues, net | $ | 209.6 | $ | 199.8 | |||||||
| Gross profit | 69.8 | 68.5 | |||||||||
| Amortization of intangible assets | 0.6 | 0.5 | |||||||||
| Non-GAAP gross profit | $ | 70.4 | $ | 69.0 | |||||||
| Gross margin % | 33.3 | % | 34.3 | % | |||||||
| Non-GAAP gross margin % | 33.6 | % | 34.5 | % | |||||||
| SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE RECONCILIATION | |||||||||||
| Selling, general, and administrative | $ | 32.7 | $ | 33.8 | |||||||
Amortization of intangible assets | 0.4 | 0.4 | |||||||||
Restructuring charges | 0.2 | 0.7 | |||||||||
| Non-ordinary course litigation | 2.3 | 1.2 | |||||||||
| Other non-operational costs | — | 0.4 | |||||||||
| Non-GAAP selling, general, and administrative expense | $ | 29.8 | $ | 31.1 | |||||||
| OPERATING EXPENSE RECONCILIATION | |||||||||||
| Total operating expenses | $ | 54.4 | $ | 57.3 | |||||||
| Amortization of intangible assets | 0.4 | 0.4 | |||||||||
| Restructuring charges | 0.2 | 0.7 | |||||||||
| Non-ordinary course litigation | 2.3 | 1.2 | |||||||||
| Other non-operational costs | — | 0.4 | |||||||||
| Non-GAAP operating expense | $ | 51.5 | $ | 54.6 | |||||||
| VAREX IMAGING CORPORATION RECONCILIATION BETWEEN GAAP AND NON-GAAP FINANCIAL MEASURES (Unaudited) | |||||||||||
| Three Months Ended | |||||||||||
| (In millions, except per share amounts) | January 2, 2026 | January 3, 2025 | |||||||||
| OPERATING INCOME RECONCILIATION | |||||||||||
| Operating income | $ | 15.4 | $ | 11.2 | |||||||
| Amortization of intangible assets (includes amortization impacts to cost of revenues) | 1.0 | 0.9 | |||||||||
| Restructuring charges (includes restructuring impact to cost of revenues) | 0.2 | 0.7 | |||||||||
| Non-ordinary course litigation | 2.3 | 1.2 | |||||||||
| Other non-operational costs (includes other non-operational impacts to cost of revenues) | — | 0.4 | |||||||||
| Total operating income adjustments | 3.5 | 3.2 | |||||||||
| Non-GAAP operating income | $ | 18.9 | $ | 14.4 | |||||||
| Operating margin % | 7.3 | % | 5.6 | % | |||||||
| Non-GAAP operating margin % | 9.0 | % | 7.2 | % | |||||||
| INCOME BEFORE TAXES RECONCILIATION | |||||||||||
| Income before taxes | $ | 3.8 | $ | 2.5 | |||||||
| Total operating income adjustments | 3.5 | 3.2 | |||||||||
| Loss from equity-method investments | 3.2 | 1.7 | |||||||||
| Other non-operational costs | 0.6 | 0.1 | |||||||||
| Total income before taxes adjustments | 7.3 | 5.0 | |||||||||
| Non-GAAP income before taxes | $ | 11.1 | $ | 7.5 | |||||||
| INCOME TAX EXPENSE RECONCILIATION | |||||||||||
| Income tax expense | $ | 1.4 | $ | 2.6 | |||||||
| Tax effect on non-GAAP adjustments | (1.6) | (0.4) | |||||||||
| Non-GAAP income tax expense | $ | 3.0 | $ | 3.0 | |||||||
| VAREX IMAGING CORPORATION RECONCILIATION BETWEEN GAAP AND NON-GAAP FINANCIAL MEASURES (Unaudited) | |||||||||||
| Three Months Ended | |||||||||||
| (In millions, except per share amounts) | January 2, 2026 | January 3, 2025 | |||||||||
| NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATION | |||||||||||
| Net income (loss) attributable to Varex | $ | 2.3 | $ | (0.3) | |||||||
| Total income before taxes adjustments | 7.3 | 5.0 | |||||||||
| Effective tax rate on non-GAAP adjustments % | 21.9 | % | 8.0 | % | |||||||
| Tax effect on non-GAAP adjustments | (1.6) | (0.4) | |||||||||
| Non-GAAP net income | 8.0 | 4.3 | |||||||||
| Diluted net income (loss) per share | 0.05 | (0.01) | |||||||||
| Non-GAAP diluted net income per share | $ | 0.19 | $ | 0.10 | |||||||
| ADJUSTED EBITDA RECONCILIATION | |||||||||||
| Net income (loss) attributable to Varex | $ | 2.3 | $ | (0.3) | |||||||
| Interest expense | 7.9 | 7.9 | |||||||||
| Income tax expense | 1.4 | 2.6 | |||||||||
| Depreciation | 5.7 | 6.2 | |||||||||
| Amortization | 1.1 | 0.9 | |||||||||
| Share-based compensation | 3.8 | 4.1 | |||||||||
| Restructuring charges | 0.2 | 0.7 | |||||||||
| Non-ordinary course litigation | 2.3 | 1.2 | |||||||||
| Loss from equity-method investments | 3.2 | 1.7 | |||||||||
| Other non-operational costs | 0.6 | 0.5 | |||||||||
| Adjusted EBITDA | $ | 28.5 | $ | 25.5 | |||||||
Reconciliation of 2025 Non-GAAP Financial Information As Previously Reported to 2025 Non-GAAP Financial Results as per Updated Policy - Excluding gains and losses from equity-method investments
(Unaudited)
We annually review our non-GAAP policy to determine whether any changes to the policy should be made. As part of our review, we considered a strategic shift at one of our equity method investees. Because of this, and because we do not control operations of either of our equity method investments, we believe that the results of these businesses no longer provide investors with information helpful to evaluate our ongoing operations. As such, we have modified our non-GAAP policy to exclude the gains and losses from our equity method investments. The gains and losses on the company's equity-method investments in privately-held companies are recorded to other expense, net, in the company’s Condensed Consolidated Statements of Operations. This updated non-GAAP policy will become the basis for the company’s comparisons going forward in fiscal year 2026 and is reflected in its 2026 guidance. The reconciliations below reflect the application of the new policy as if it had been adopted at the beginning of fiscal year 2025. Please refer to "Reconciliation between GAAP and non-GAAP Financial Measures" below for a reconciliation of non-GAAP items to the most comparable GAAP measures.
| INCOME BEFORE TAXES RECONCILIATION | |||||||||||||||||||||||||||||
| (In millions) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | FY 2025 | ||||||||||||||||||||||||
| Non-GAAP income before taxes (as reported) | $ | 5.8 | $ | 14.9 | $ | 10.0 | $ | 17.8 | $ | 48.5 | |||||||||||||||||||
| Loss (income) from equity-method investments | 1.7 | 1.9 | (1.4) | 0.1 | 2.3 | ||||||||||||||||||||||||
| Non-GAAP income before taxes (as adjusted) | $ | 7.5 | $ | 16.8 | $ | 8.6 | $ | 17.9 | $ | 50.8 | |||||||||||||||||||
| INCOME TAX EXPENSE RECONCILIATION | |||||||||||||||||||||||||||||
| (In millions) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | FY 2025 | ||||||||||||||||||||||||
| Non-GAAP income tax expense (as reported) | $ | 2.7 | $ | 3.2 | $ | 2.4 | $ | 2.5 | $ | 10.8 | |||||||||||||||||||
| Tax effect on non-GAAP adjustment | (0.3) | 1.1 | (0.9) | (0.4) | (0.5) | ||||||||||||||||||||||||
| Non-GAAP income tax expense (as adjusted) | $ | 3.0 | $ | 2.1 | $ | 3.3 | $ | 2.9 | $ | 11.3 | |||||||||||||||||||
| NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATION | |||||||||||||||||||||||||||||
| (In millions, except per share amounts) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | FY 2025 | ||||||||||||||||||||||||
| Non-GAAP net income (as reported) | $ | 2.9 | $ | 11.5 | $ | 7.6 | $ | 15.3 | $ | 37.3 | |||||||||||||||||||
| Loss (income) from equity-method investments | 1.7 | 1.9 | (1.4) | 0.1 | 2.3 | ||||||||||||||||||||||||
| Tax effect on non-GAAP adjustment | (0.3) | 1.1 | (0.9) | (0.4) | (0.5) | ||||||||||||||||||||||||
| Non-GAAP net income (as adjusted) | $ | 4.3 | $ | 14.5 | $ | 5.3 | $ | 15.0 | $ | 39.1 | |||||||||||||||||||
| Non-GAAP net income adjusted for interest add-back (as reported) | $ | 2.9 | $ | 13.1 | $ | 7.6 | $ | 15.3 | $ | 37.3 | |||||||||||||||||||
| Loss (income) from equity-method investments | 1.7 | 1.9 | (1.4) | 0.1 | 2.3 | ||||||||||||||||||||||||
| Tax effect on non-GAAP adjustment | (0.3) | 1.1 | (0.9) | (0.4) | (0.5) | ||||||||||||||||||||||||
| Non-GAAP net income adjusted for interest add-back (as adjusted) | $ | 4.3 | $ | 16.1 | $ | 5.3 | $ | 15.0 | $ | 39.1 | |||||||||||||||||||
| Diluted shares | 41.1 | 51.2 | 41.5 | 41.8 | 41.4 | ||||||||||||||||||||||||
| Diluted EPS (as reported) | $ | 0.07 | $ | 0.26 | $ | 0.18 | $ | 0.37 | $ | 0.90 | |||||||||||||||||||
| Diluted EPS (as adjusted) | $ | 0.10 | $ | 0.31 | $ | 0.13 | $ | 0.36 | $ | 0.94 | |||||||||||||||||||
| ADJUSTED EBITDA RECONCILIATION | |||||||||||||||||||||||||||||
| (In millions) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | FY 2025 | ||||||||||||||||||||||||
| Adjusted EBITDA (as reported) | $ | 23.8 | $ | 34.3 | $ | 28.9 | $ | 34.9 | $ | 121.9 | |||||||||||||||||||
| Loss (income) from equity-method investments | 1.7 | 1.9 | (1.4) | 0.1 | 2.3 | ||||||||||||||||||||||||
| Adjusted EBITDA (as adjusted) | $ | 25.5 | $ | 36.2 | $ | 27.5 | $ | 35.0 | $ | 124.2 | |||||||||||||||||||
Discussion of Non-GAAP Financial Measures
This press release includes non-GAAP financial measures derived from the company's Condensed Consolidated Statements of Operations. These measures are not presented in accordance with, nor are they a substitute for U.S. generally accepted accounting principles, or GAAP. These measures include: non-GAAP gross profit; non-GAAP gross margin; non-GAAP operating expense; non-GAAP operating earnings; non-GAAP operating earnings margin; non-GAAP earnings before taxes; non-GAAP net earnings; non-GAAP net earnings per diluted share, non-GAAP dilutive shares; and non-GAAP EBITDA. The company is providing a reconciliation above of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. The company is unable to provide without unreasonable effort a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability and limited visibility of the excluded items discussed.
The company utilizes a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of its business, in making operating decisions, and forecasting and planning for future periods. The company considers the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of its business by excluding unusual and one-time costs. The company believes that disclosing non-GAAP financial measures provides useful supplemental data that allows for greater transparency in the review of its financial and operational performance. The company also believes that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating its operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.
Non-GAAP measures include the following items:
Amortization of intangible assets: The company does not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition or asset purchase. The company believes that excluding amortization of intangible assets allows the users of its financial statements to better review and understand the historic and current results of its operations, and also facilitates comparisons to peer companies.
Purchase price accounting charges to cost of revenues: The company may incur charges to cost of revenues as a result of acquisitions. The company believes that excluding these charges allows the users of its financial statements to better understand the historic and current cost of its products, its gross margin, and also facilitates comparisons to peer companies.
Restructuring charges: The company incurs restructuring charges that result from events which arise from unforeseen circumstances and/or often occur outside of the ordinary course of its on-going business. Although these events are reflected in its GAAP financials, these unique transactions may limit the comparability of its on-going operations with prior and future periods.
Acquisition and integration related costs: The company incurs expenses or benefits with respect to certain items associated with its acquisitions, such as transaction costs, changes in fair value of acquisition related hedges, changes in the fair value of contingent consideration liabilities, gain or expense on settlement of pre-existing relationships, etc. The company excludes such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of its on-going business. The company also incurs expenses or benefits with respect to certain items associated with its acquisitions, such as integration costs relating to acquisition costs incurred prior to closing and up to 12 months after the closing date of the acquisition.
Impairment of goodwill: The company may incur impairment charges that result from events which arise from unforeseen circumstances and/or often occur outside of the ordinary course of its on-going business and such charges may limit the comparability of its on-going operations with prior and future periods.
Non-ordinary course litigation: The company may incur charges that result from non-ordinary course litigation matters such as certain intellectual property disputes and joint venture litigation. Litigation matters that are part of the ordinary course of the company’s business, such as product liability claims, employment related matters and commercial contract disputes, are not excluded.
Other non-operational costs: Certain items may be non-recurring, unusual, infrequent and directly related to an event that is distinct and non-reflective of the company’s ongoing business operations. These may include such items as legal settlements, inventory write-downs for discontinued products, cost of facilities no longer in use, extinguishment of debt and hedge costs, environmental settlements, governmental settlements including tax settlements, and other items of similar nature.
Non-operational tax adjustments: Certain tax items may be non-recurring, unusual, infrequent and directly related to an event that is distinct and non-reflective of the company’s normal business operations. These may include such items as the retroactive impact of significant changes in tax laws, including changes to statutory tax rates and one-time tax charges.
Tax effects of operating earnings adjustments: The company applies its non-GAAP adjustments to the GAAP pretax income to calculate the non-GAAP effective tax rate. This application of its non-GAAP effective tax rate excludes any discrete items, as defined in the guidance for accounting for income taxes in interim periods, or any other non-operational tax adjustments.
Dilution offset from convertible notes hedge transaction: In connection with the issuance of the company’s Convertible Senior Unsecured Notes (the Convertible Notes) in June 2020, the company entered into convertible note hedge transactions (the Hedge Transactions) to reduce the potential dilutive effect on common shares upon the potential conversion of the Convertible Notes. GAAP diluted shares outstanding includes the incremental dilutive shares from the company’s Convertible Notes. Under GAAP, the anti-dilutive impact of the Convertible Note Hedge Transactions is not reflected in GAAP diluted shares outstanding. In periods in which the average stock price per share exceeds $20.81 and the company has GAAP net income, the non-GAAP diluted share count includes the anti-dilutive impact of the company’s Hedge Transactions, which reduces the potential dilution that otherwise would occur upon conversion of the company’s Convertible Notes. The company believes non-GAAP diluted shares is a useful non-GAAP metric because it provides insight into the offsetting economic effect of the Hedge Transactions against potential conversion of the Convertible Notes.
Gains and losses on equity-method investments: The company's net income (loss) is impacted by gains and losses associated with its equity-method investments in privately-held companies included in other expense, net on the Condensed Consolidated Statements of Operations. These gains and losses may arise from unforeseen circumstances and/or often occur outside of the ordinary course of the company's on-going business. By excluding these gains and losses, investors can better evaluate its operating performance period-over-period.
FAQ
How did Varex Imaging (VREX) perform financially in Q1 fiscal 2026?
Varex Imaging posted Q1 fiscal 2026 revenue of $209.6 million, up 5% year-over-year. GAAP net income attributable to Varex was $2.3 million versus a $0.3 million loss a year earlier, and non-GAAP diluted EPS increased to $0.19 from $0.10.
What were Varex Imaging’s medical and industrial revenues in Q1 2026?
In Q1 fiscal 2026, medical segment revenue was $144.8 million and industrial segment revenue was $64.8 million. Industrial revenue rose from $55.2 million a year earlier, reflecting a 17% year-over-year increase tied to strength in cargo systems and other industrial applications.
How did Varex Imaging’s profitability and margins change year-over-year?
Operating income increased to $15.4 million from $11.2 million, and GAAP diluted EPS improved to $0.05 from a $(0.01) loss. Non-GAAP operating margin rose to 9.0% from 7.2%, while non-GAAP net income grew to $8.0 million from $4.3 million.
What is Varex Imaging’s cash and debt position after Q1 fiscal 2026?
At January 2, 2026, Varex held $119.5 million in cash and cash equivalents plus $6.1 million in marketable securities, totaling $125.6 million. Total assets were $1,098.0 million and long-term debt, net, was $366.2 million, broadly consistent with the prior fiscal year-end.
What guidance did Varex Imaging provide for Q2 fiscal 2026?
For the second quarter of fiscal 2026, Varex expects revenue between $210 million and $225 million. The company also projects non-GAAP net earnings per diluted share between $0.15 and $0.25, with guidance given only on a non-GAAP basis due to variability in excluded items.
How has Varex Imaging changed its non-GAAP reporting policy for 2026?
Beginning in Q1 fiscal 2026, Varex excludes gains and losses from equity-method investments from its non-GAAP measures. Management believes these results, recorded in other expense, net, no longer help investors evaluate ongoing operations, and has restated 2025 non-GAAP comparisons under this updated policy.
What was Varex Imaging’s adjusted EBITDA in Q1 fiscal 2026?
Adjusted EBITDA for Q1 fiscal 2026 was $28.5 million, up from $25.5 million in the prior-year quarter. This metric adds back interest, taxes, depreciation, amortization, share-based compensation, restructuring, non-ordinary course litigation, equity-method losses, and other non-operational costs.
Filing Exhibits & Attachments
4 documents
Varex Imaging Corp
NASDAQ:VREX
VREX Rankings
VREX Latest News
VREX Latest SEC Filings
Feb 10, 2026
[10-Q] Varex Imaging Corp Quarterly Earnings Report
Feb 10, 2026
[Form 4] Varex Imaging Corp Insider Trading Activity
VREX Stock Data
570.52M
41.31M
1.66%
95.51%
2.25%
Medical Devices
Electronic Components, Nec
United States
SALT LAKE CITY